Genetic diversity and evidence for acquired antimicrobial resistance in Mycobacterium tuberculosis at a large hospital in South India  by Harris, Kenneth A. et al.
Original Report 
Genetic Diversity and Evidence for Acquired 
Antimicrobial R&is&me in Mycobact&$um tuberculosk 
at a Large Hospital in South India 
Kenneth A. Harris Jr., PhD; * Umadevi Mukundan, MSc; + James M. Musser, PhD;* 
Barry N. Kreiswirth, PhD;§ and M. K. Lalitha, PhDi 
ABSTRACT 
Objectives: To assess genetic diversity and drug resistance of 
Mycobacterium tuberculosis isolates collected at Christian Med- 
ical College Hospital (CMCH), Vellore, India, between July 1995 
and May 1996. 
Materials and Methods: Isolates were subjected to IS6770- 
based restriction fragment length polymorphism (RFLP) analy- 
sis and tested for resistance to isoniazid, rifampin, ethambutol, 
streptomycin, and pyrazinamide, and DNA from selected strains 
was sequenced in regions associated with drug resistance. 
Results: One hundred and one M. tuberculosis isolates were 
collected from 87 patients with pulmonary tuberculosis. Charts 
of 69 patients were reviewed for history of tuberculosis illness 
and treatment. DNA from 29 strains was sequenced in k&G, 
rpoB, and gyrA, and sometimes pncA regions. Analysis by 
RFLP revealed a high degree of genetic diversity, with no iden- 
tifiable clusters of infection. Of the strains tested, 51% were 
resistant to at least one antibiotic, and 43% were resistant to 
more than one drug. There was a high rate of resistance 
observed in patients whose charts indicated a history of 
improperly administered tuberculosis treatment, whereas little 
drug resistance was observed in patients never previously 
treated for tuberculosis. Sequencing of genes associated with 
drug resistance revealed several previously unreported muta- 
tions in resistant strains. 
Cor~c/usions: This analysis suggests that the cases of tuber- 
culosis in the sample are largely reactivation of long-standing 
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infections and that the drug resistance among patients in 
CMCH is largely acquired or secondary rather than attribut- 
able to the spread of drug-resistant strains. 
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It is estimated that one-third of the world’s population is 
infected with Mycobacterium tuberculosis.’ Tuberculo- 
sis (TB) is the leading cause of death from a single infec- 
tious agent worldwide, and if present trends continue 
unchecked, TB deaths are predicted to increase from 3 
million in 1995 to 3.5 million in 2000.2 From the vast 
number of people with latent TB infection, approximately 
8 million develop active disease per year, maintaining a 
pool of about 16 million cases of TB worldwide.” 
Many factors contribute to the rise in TB in devel- 
oping countries such as India. There has been a recent 
increase in TB incidence worldwide, particularly in the 
developing world. Poor socioeconomic conditions, such 
as poverty, crowded living conditions, and malnutrition 
parallel high tuberculosis infection rates.3-5 Fifty percent 
of adults in India are estimated to be infected with M. 
tuberculosk6 India presently harbors approximately 30% 
of the world’s cases of tuberculosis, or about 3.8 million 
active cases of disease, and the prevalence of active TB 
in the general Indian population in 1995 was estimated 
to be 422 per 100,000.6 The most recent survey of the 
prevalence of TB in an area served by Christian Medical 
College Hospital (CMCH), a rural section of the North 
Arcot Ambedkar District in Tamil Nadu, South India, found 
a lower prevalence of 241 per 100,000 in the early 
1980s.’ 
in alarming aspect of the tuberculosis pandemic is 
the development and spread of drug-resistant strains of 
M. tuberculosis. Multidrug resistance (MDR) is defined 
by the World Health Organization as resistance to both 
rifampin and isoniazid.8 Multidrug resistant strains of TB 
have gravely compounded the problem posed by this 
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disease in India; therefore, it is important to determine the 
modes of development and extent of spread of MDR 
strains in India. This study is an example of a preliminary 
effort to do so, using IS62 10 restriction fragment length 
polymorphism (RPLP) analysis and sequencing of drug 
resistance mutations in TB strains isolated at a large hos- 
pital in South India. Christian Medical College Hospital in 
Vellore, Tamil Nadu, is a major tertiary care facility that 
serves the North Arcot Ambedkar District and also 
attracts patients from all over India and South Asia. 
Together these data demonstrate the diversity of geno- 
types and patterns of drug resistance present in a cross- 
section of TB strains found in patients from across India. 
MATERIALS AND METHODS 
Mycobacterial Strains and Epidemiologic Features 
A retrospective study was conducted of 101 M. tubercu- 
losis isolates from sputum samples collected from 87 
patients with TB, at CMCH between July 1995 and May 
1996. Mycobacteria were grown on Lowenstein-Jensen 
slants. These isolates represent all of the sputum cultures 
positive for M. tuberculosis accumulated at the CMCH 
Department of Clinical Microbiology during this period. 
Of the 101 isolates in the sample, 63 had been tested for 
drug susceptibility Charts for 69 of the 87 patients were 
available for review, and any history of treatment for 
tuberculosis was noted. Inadequate treatment was defined 
as any form of improper drug therapy either before or 
during treatment at CMCH, including taking medications 
irregularly; taking fewer medications than prescribed; or 
being treated with an insufficient regimen, such as a one- 
or two-drug protocol for any length of time. Lack of pre- 
vious treatment was confirmed only if specifically men- 
tioned as such in the chart. If there was no mention of 
prior treatment history in the chart, the patient was 
included in the same “unknown” category as those whose 
charts were unavailable for review. 
DNA Analysis and Drug Susceptibility 
DNA was extracted from mature cultures by standard 
methods9 Restriction fragment length polymorphism pat- 
terns were compared with each other and with the data- 
base at the Public Health Research Institute (PHRl) TB 
Center in New York City, using BioImage Whole Band 
Analyzer (BioImage, Ann Arbor, MI). The PHRI database 
contains approximately 6500 RPLP patterns, collected 
primarily in New York City over the past 5 years. These 
methods were successfully applied to isolates from 77 of 
the 87 patients; insufficient or degraded DNA from iso- 
lates from 10 patients made RPLP analysis impossible. 
Drug susceptibility assays were performed at CMCH, 
using standard methods. 1o.11 Because of technical diff- 
culties inherent to pyrazinamide-susceptibility testing, 
susceptibility but not resistance can be reliably deter- 
mined. Extracted DNA was sequenced by standard poly- 
merase chain reaction (PCR) methods, using probes 
specific to genes associated with drug resistance.” DNA 
isolates from the study sample were randomly selected 
for sequencing. Unfortunately mycobacterial strains could 
not be transported from India, therefore repeat drug sus- 
ceptibility studies could not be conducted when 
sequence data conflicted with susceptibility data. 
RESULTS 
Clinical Characteristics 
In the 10 cases where multiple isolates were obtained 
from a patient, the same RFLP pattern was observed in 
all isolates from that patient. Most TB patients at CMCH 
are diagnosed by acid-fast smear alone, and therefore, the 
87 patients in the study from whom the 101 M. tuber- 
culosis isolates were obtained are a small subset of the 
thousands of TB patients treated at CMCH each year. Con- 
sistent with the previously observed higher TB incidence 
in males in India,‘” 71% of the study patients were male. 
The age range of patients was 12 to 72 years (mean, 37 
y; median, 35 y). Patients came from 10 Indian states, 
Nepal, and Bhutan (Table l), and of the patients whose 
origins were known, about half (49%) came from the 
North Arcot Ambedkar (NAA) District in northern Tamil 
Nadu state, of which Vellore is the administrative head- 
quarters. Most of the patients (76%) were from south 
India (Tamil Nadu or the adjacent states of Andhra 
Pradesh and Karnataka). 
Table 1. Geographic Origins of the 87 Study Patients 
Number of Total 
Patients Patients 
Region @I in Area 
Number of patients of known origin (n = 75) 
Vellore (town and adjacent area) 17 (23) 
NAA District (other than Vellore) 20 (27) 
Total NAA District 37 (49) 
Tamil Nadu (outside of NAA District) 11 (15) 
Total Tamil Nadu 48 (64) 
Andhra Pradesh 7 
Karnataka 2 
Total South India 57 (76) 
Madhya Pradesh 1 
Uttar Pradesh 1 
Bihar 1 
West Bengal 9 
Assam 1 
Manipur 2 
Mizoram 1 
Nepal 1 
Bhutan 1 
Unknown/chart not available (n = 12) 
NAA = North Arcot Ambedkar. 
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Table 2. Drug Resistance and History of Inadequate Anti-tuberculosis Chemotherapy 
Number Resistant to 
Inadequate 
An? 
Yes 
No 
Unknown 
Total 
Delhi states 
Number 
in study* 
27 (31) 
18 (21) 
42 (48) 
87 (100) 
Number 
Tested+ 
22 (35) 
11 (17) 
30 (48) 
63 (72) 
/soniazid* 
19 (86) 
12” (40) 
31 (49) 
Rifampin’ 
16 (73) 
0 
6 (20) 
22 (35) 
EthambutoF 
6 (27) 
i (10, 
9 (14) 
StreptomycinS 
8 (36) 
0 
8 (27) 
16 (25) 
Other* 
2 (9) 
1 (9) 
1 (3) 
4 (6) 
2240 (28.8) (14.0) (7.0) (18.1) 
Figures in parentheses CknOte percentages *of total subjects; +of total tested; *of number tested in the category. All = anti-tuberculosis chemotherapy; other = strain 
found resistant to another drug (capreomycin, ciprofloxacin, ofloxacin, ethionamide, or cyctoserine; most strains tested for resistance only to the four first-fine drugs); 
sdata from WHOMATLD study for comparisonz8 
RFLP Strain Typing by IS6120 
From the 87 patients, 77 isolates were successfully typed. 
There were no identifiable clusters of patients infected 
with the same strain; 49 strains (64%) had patterns unique 
both to the group and to the PHRl database. Similarity 
among strains was not significantly correlated with fac- 
tors such as geographic origin of patients. 
When few copies of the insertion sequence are pre- 
sent, IS6110-based typing alone is not sufficient to dif- 
ferentiate these strains and determine if any clusters of 
patients infected with the same strain are present. In this 
study, 22 isolates (29%) had only a single copy of the 
IS6110 insertion sequence; in 19 of these isolates, the 
fragment containing the insertion sequence was approx- 
imately 1.5 kilobases (kb), a size seen in the strains des- 
ignated BE in the PHRI database.‘* Strains with a single 
band in this position are common; 123 BE strains are pre- 
sent in the database, dating from 1992. In two “single- 
band” isolates the fragment size was approximately 5.0 
kb (designated BE3) and in one the fragment was 1.1 kb, 
a pattern new to the PHIU database (designated BEG). A 
large proportion of single-band isolates has been observed 
in other RFLP studies in India and southeast Asia.i5,” 
Only three strains in the sample with a large number 
of copies of 1~6110 matched patterns in the PHRI data- 
base. Strain GDl, isolated from a man from the NAA Dis- 
trict, had an KFLP pattern that differed by one band from 
a strain isolated in Kenya in 1995. Strain EZ2, also from a 
NAA District man, matched exactly with a strain isolated 
from a New Jersey man in 1996. Strain E, from a woman 
from Thiruchchirapalli, Tamil Nadu, matched a large New 
York City cluster, with 60 examples in the PHRI database, 
collected from 1991 to 1996. None of the matches are 
known to be from patients of Indian origin. The matches 
indicate that there could be epidemiologic connections 
between the CMCH patients and those in the database, but 
more information is required to trace these connections. 
Drug Resistance 
Drug susceptibility testing was performed at CMCH for 
63 of the isolates in the sample; 32 of 63 patients (51%) 
were infected with a strain resistant to at least one drug. 
The most common resistance was to isoniazid (49% resis- 
tant), followed by rifampin (35%) streptomycin (25%) 
and ethambutol (14%) (Table 2). It was determined that 
74% of the isolates were susceptible to pyrazinamide. 
The mean age of the patients with resistant strains (39 y) 
was not significantly different from that of patients with 
susceptible strains (36 y) or the mean of all patient ages 
(37 Y). 
Patient charts were reviewed to correlate drug resis- 
tance with previous TB and treatment. As indicated in 
Table 2,31% of the patients in the sample were reported 
to have a history of inadequate chemotherapy, as previ- 
ously defmed (see Materials and Methods); 2 1% had never 
been treated with antibiotics for TB; and drug therapy 
history for the rest of the patients either was not recorded 
in the chart, was unknown, or the charts of the patients 
Table 3. Pattern of Drug Resistance with History of Inadequate Anti-tuberculosis Chemotherapy 
Number Resistant to 
Inadequate Number 7 Drug 2 Drugs 3 Drugs 4 Drugs 
ATT? Tested I S IR IE IS IRE IRS /ES I R ES Total (%j 
Yes 22 1 0 7* 0 1 3 4+ 1 2 19 (86) 
No 11 0 0 0 0 0 0 0 0 0 05 
Unknown 30 3 1 0 1 2 1 4* 0 13 (43) 
Total (%) 63 5 (8) 11 (17) 13 (21) &5, 32 (51) 
Delhi state (%)” 2240 (10.9) (10.9) (7.1) (3.5) (32.4) 
ATT = anti-tuberculosis chemotherapy: I = isoniazid; S = streptomycin; R = rifampin; E = ethambutol. 
*One strain also resistant to ciprofloxacin and ethionamide; tone strain also resistant to capreomycin, ofloxacin, and cycloserine; *one strain also resistant to 
ciprofloxacin, capreomycin. and cycloserine; Bone othewise pan-susceptible strain resistant to cycloserine; ‘data from WHONATLD study for comparison.28 
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Region 
Table 4. Extent of Drug Resistance by Geographic Origin of Study Patients 
Resistant to at Least One Drug 
Number of Patients Number Tested (?A) n 1%) 
MDR 
n (%j 
North Arcot Ambedkar District 37 23 (62) 10 (43) 6 (26) 
South India 57 39 (68) 17 (44) IO (26) 
North-northeast India and subcontinent 18 15 (83) 11 (73) 9 (60) 
MDR = multidrug resistant. 
were not available for review. Drug resistance in the pre- 
viously untreated group may be interpreted as a marker 
for primary resistance (i.e., new infection with a drug- 
resistant strain). Of 11 patients in the sample never 
treated for TB, only one was infected with a drug-resis- 
tant strain. Acquired resistance likely was present among 
the patients with a history of inadequate treatment, as 
the rates of resistance to first-line drugs among this group 
were high: 86% were resistant to isoniazid, 73% were resis- 
tant to rifampin, and 73% were resistant to both and, 
therefore, qualify as MDR strains. 
The pattern of drug resistance in the sample is 
shown in Table 3. Multidrug resistance was common: the 
largest number of the resistant strains were resistant to 
three first-line drugs. Of 22 patients with a history of 
inadequate chemotherapy, 19 (86%) had drug-resistant 
TB and only one of these was resistant to only one drug. 
Resistance to both isoniazid and rifampin (MDR) was 
seen in 22 (69%) of the 32 resistant strains. 
Of the patients from South India who were tested, 
44% had drug-resistant TB, and 26% had MDR TB (Table 
4). A much larger proportion of the patients travelling to 
CMCH from North and Northeast India, Nepal, and Bhutan 
had drug susceptibilities performed (83%) and had drug- 
resistant TB or MDR TB (73% and 60%, respectively). 
Sequencing of Genes Associated with Drug 
Resistance and Evolution 
Antibiotic resistance in M. tuberculosis is mediated by 
chromosomal mutations rather than by plasmids carrying 
drug resistance genes. Mycobacterium tuberculosis genes 
in which mutations are associated with drug resistance 
have been identified for several antibiotics: rpoB 
(rifampin), rrs and rpsL (streptomycin), katG and inhA 
(isoniazid), gyrA (fluoroquinolones), and pncA (pyrazi- 
namide).12 DNA from 29 of the strains in the study sam- 
ple was sequenced in the resistance-associated regions of 
katG, rpoB, and gyrA, and 13 of these were also 
sequenced in the pncA region. 
Mutations in katG were detected in 18 of the 29 
strains sequenced (Table 5). Two of these mutations had 
not been previously reported: strain 35, with a single 
point mutation (428 Gly to Arg); and strain 44, with one 
novel point mutation (328 Asp to Ala) as well as a poly- 
morphism seen in a large division of M. tuberculosis 
strains (463 Arg to Leu).l* Ten of the mutated strains 
occurred in patients with a known history of inadequate 
chemotherapy, whereas only one was from a patient with 
no prior drug therapy (Table 6). This observation is consis 
tent with the hypothesis that these are examples of acquired 
resistance (i.e., these mutations arose in these patients). 
Mutations in rpoB that result in amino acid changes 
were identified in 12 of the 29 strains sequenced (see 
Table 5). Two mutations had not been previously 
reported: strain 82, with two amino acid changes (516 
Asp to Glu; 522 Ser to Leu); and strain 58, with three 
point mutations changing two amino acids (525 Thr to 
Thr; 526 His to Pro; 527 Lys to Gin).” Eight of the mutated 
strains occurred in patients with a known history of inad- 
equate chemotherapy compared to one from a patient 
without prior drug therapy (see Table 6). 
Two of 13 strains sequenced in the pncA region pos- 
sessed single point mutations that change the amino acid 
sequence of pyrazinamidase: strain 35 (132 Gly to Asp) 
and strain 78 (His to Arg) (Table 7). Both of these muta- 
tions, which previously have been reported, were from 
patients with known histories of inadequate chemother- 
apy (see Table 6).” 
None of the 29 strains sequenced had mutations in 
gyrA that are expected to result in drug resistance. How- 
ever, two of these strains (5 and 82) were tested for 
ciprofloxacin susceptibility and strain 5 was found to be 
resistant. In addition, strain 1 was reported resistant to 
ofloxacin. The resistance seen in these two strains could 
be attributable to mutations in the B subunit of gyrase 
(the gyrB region). 
Recently, groups of TB strains from around the world 
have been subdivided into evolutionarily related groups 
based on sequences of the BaK; and gyrA genes.‘: It is 
thought that the ancestral group (Group 1) is described 
by katG 463 Leu and gyrA 95 Thr; these sequences are 
shared by the other M. tuberculosis complex species, M. 
bovis, M. microti, and M. africanurn. Group 2 is charac- 
terized by a change to katG 463 Arg and in Group 3 gyrA 
is Ser; these polymorphisms are found only in M. tuber- 
culosis. Twenty of the strains sequenced (69%) were 
Group 1 strains and only two were Group 3. Two strains 
had deletions in katG, and it could not be determined 
whether they were Group 1 or Group 2. Sreevatsan and 
colleagues present the hypothesis that Group 3 strains, 
found largely in Latin America and Africa, arose and 
spread approximately 450 years ago.” The predominance 
of Group 1 strains in India is consistent with the notion 
that these strains have been endemic there for a much 
longer time. 
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Table 5. Drug Resistance Predicted from Sensitivity Testing at CMCH and from katG and rpoB Gene Sequencing Data 
lsoniazid Resistance 
Reference 
Rifampin 
Interpretation 
Number (Numbezf Bands) Phenotypic 
Interpretation 
Genotypic katG Sequence Phenotypic Genotypic rpoB Sequence 
H 
R 
R 
S 
R 
S 
R 
S 
S 
S 
R 
R 
S 
S 
R 
R 
S 
R 
S 
S 
S 
R 
R 
R 
R 
R 
R 
R 
R 
315&R; 463R>L 
315&T; 463R>L 
315S>T; 463R>L 
463R>L 
315S>T; 463R>L 
463R>L 
315S>T 
463R>L 
wt 
463R>L 
315S>N; 463R>L 
428G>R l 
w t  
463R>L 
329D>A *; 463R>L 
315S>T: 463R>L 
463R>L 
315S>T; 463RzL 
463R>L 
wt 
463R>L 
315S>T; 463R>L 
315S>N; 463R>L 
deletion 
deletion 
315S>T 
315S>T; 463R>L 
315S>T; 463R>L 
315S>T; 463R>L 
R 
S 
; 
R 
S 
S 
S 
S 
S 
S 
S 
S 
S 
R 
S 
S 
S 
S 
S 
R 
S 
S 
R 
R 
R 
S 
E 
R 
S 
S 
S 
R 
R 
S 
S 
S 
R 
S 
S 
s” 
S 
R 
S 
R 
S 
R 
S 
R 
S 
R 
2 
S 
R 
S 
z 
S 
S 
R 
R 
R 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
R 
S 
S 
R 
R 
s” 
S 
R 
R 
R 
R 
R 
R 
S 
526H>Y 
531 S>L 
WI 
wt 
wt 
wt 
wt 
wt 
wf 
wt 
wt 
wt 
wt 
wt 
531 S>L 
wt 
wt 
513 Q>K 
525T>T; 526H>P; 
527K>E * 
531 S>L 
wt 
wt 
533L>P 
531 s>w 
526HzC 
516D>E l ; 522S>L 
531 S>L 
526H>R 
wt 
FP = fingerprint; *novel mutation; wt = wild type. 
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Table 6. Presence of Mutations in Four Drug Resistance-Associated M. tuberculosis Genes Correlated 
with History of Inadequate Anti-tuberculosis Chemotherapy 
katG katG rpol3 rpoB gYrA pnd pnd 
Inadequate AT? R S R S S R S 
Yes 10 2 8 4 12 2 6 
No 1 1 1 1 2 0 0 
Unknown 7 8 3 12 15 0 5 
Total 18 11 12 17 29 2 11 
ATT = anti-tuberculosis chemotherapy: R = mutation consistent with resistance to drug: S = wild-type sequence or mutation not associated with drug resistance; 
drugs associated with the genes shown are: kaTG, isoniazid; rpoB, rifampicin; gyrA, fluoroquinolones; pncA, pyrazinamide. 
DISCUSSION 
Restriction Fragment Length 
Polymorphism Strain Qping 
Typing by RFLP has shown that diversity of strains varies 
widely in different regions of the world. In east Asia, a 
single family of RFLP patterns dominates the population 
of TB strains.18 In Madras, RFLP typing studies found a 
high proportion (40%) of strains with zero or one copy 
of 1~6110.~~ This situation reduces the usefulness of 
IS61 1 O-based RFLP typing for epidemiologic analysis, but 
it does not render the method useless. The other 60% of 
strains in that study displayed a wide diversity of RFLP 
patterns, in contrast to observations in east Asia.19x20 
Other probes also may be used for RFLP typing in pop- 
ulations where IS6110 is less useful; the direct-repeat 
(DR) probe was used in Madras to demonstrate the pres- 
ence of reactivation of incompletely cured infections 
after treatment.” 
Strain type clustering is not necessarily expected in 
the subset of patients from regions distant from CMCH, 
as the sample is small and these patients are not likely to 
have been in contact when they acquired TEi infections. 
However, there is a lack of clustering even among patients 
from Vellore. Clustering of patients with the same strain 
would suggest that patients are ill with infections 
acquired around the same time and in the same place. 
Whereas this small sample may not detect the full extent 
of any clustering that may be present among TB strains 
in Vellore, the lack of clustering in the sample is consis- 
tent with the explanation that these TB cases are attrib- 
utable to reactivation of previously acquired infections. 
Given the high prevalence of TB infection in India, the 
result is not surprising, because these patients had oppor- 
tunities to be exposed to TB throughout their lives. 
Drug Resistance 
Various studies reveal that the patterns of drug resistance 
in India vary from region to region, but that the problem 
is great.8.1~.2’-24 The studies differ in their methodologies 
and populations studied. In Jaipur in 1993, resistance to 
at least one drug was seen in 19.9% of cases.25 Primary 
resistance (acquisition of strains that are already drug- 
resistant) was observed in TB infections of kidney trans- 
plant patients at CMCH from 1991 to 1993.” One study, 
conducted from 1985 to 1989, determined that 25% of 
patients with TB in North Arcot, Tamil Nadu, had a strain 
resistant to one of three first-line drugs, isoniazid (I), 
rifampin (R), or streptomycin (S>.26 Another study 
reported the prevalence of primary resistance in South 
India to be 4.8% for I, 5.7% for S, and 0.12% for R.27 The 
resistance rates calculated by the World Health Organi- 
zation (WHO)/International Union against Tuberculosis 
and Lung Disease (IUATLD) for Delhi state from 1994 to 
1997 were lower than observed in this study, but the 
trend in drug resistance is similar to that observed here 
(see Table 2).28 The WHO study observed significantly 
less resistance to multiple drugs than is present in the 
sample studied here (see Table 3). 
Owing to cost constraints, drug susceptibility studies 
and even mycobacterial cultures are not routinely ordered 
for TB patients at CMCH. The studies are performed either 
if cost is not a factor or if drug resistance is suspected, 
either clinically or from a known history of inadequate 
treatment. Therefore, the sample studied here undoubt- 
edly is enriched for drug resistant strains. The subset from 
North India enriches the sample further for serious drug 
resistance, because patients with unsuccessfully treated 
Table 7. Pyrazinamide Resistance Predicted from Sensitivity 
Testing at CMCH and from pncA Gene Sequencing Data 
Pyrazinamide Resistance 
Reference Interpretation pnd 
Number Phenotypic Genotypic Sequence 
1 S S 65 S>S 
5 NA S wt 
28 S S wt 
34 S S 65 S>S 
35 NA R 132 G>D 
58 S S 65 S>S 
62 
63 z 
S wt 
S wt 
68 NA S wt 
75 
78 El 
S wt 
51 H>R; 65 S>S 
83 S F- wt 
87 NA S wt 
S = wild-type sequence or mutation not associated with drug resistance; R = 
mutation consistent with resistance to drug; NA = not assessed; wt = wild 
type.‘* 
146 International Journal of Infectious Diseases / Volume 4, Number 3 
TB may seek treatment at national referral centers such as 
CMCH. The correlation in this sample between prior mad- 
equate treatment and drug resistance as well as the lack 
of drug resistance in the patients with no prior treatment 
does suggest that drug resistance in the sample was largely 
acquired rather than primary. Unfortunately, the exact 
details of each history of inadequate treatment were gen- 
erally not known or not documented in the chart. There- 
fore the effects of various forms of inadequate therapy 
(e.g., too short a course, too few drugs, irregular dosing) 
on the development of drug resistance could not be 
assessed in this study. Although the present study suggests 
that only a small proportion of drug resistance may be 
attributable to primary resistance, the growing rates of 
drug resistance in India set the stage for the spread of 
drug-resistant TB in the future. 
In general the DNA sequencing predictions corre- 
lated well with the drug susceptibility test results from 
CMCH. Four strains were found to be isoniazid-resistant 
but lacked mutations in the region of k&G sequenced, 
and may have had mutations elsewhere in La& or in 
i&A, that also confer resistance. It is more difficult to 
explain the two strains that were reported susceptible 
to isoniazid but had k&G mutations known to confer 
resistance (82 and 99; see Table 5). Strain 82 also had a 
novel mutation in rpoB at position 5 16 as well as a muta- 
tion at position 522 known to confer resistance, yet it 
was reported susceptible to rifampin. Four additional 
strains were reported resistant to rifampin but no rpoB 
mutations were found. Since over 95% of rifampin-resis- 
tant strains have mutations in this region of rpoB,'* these 
cases are likely attributable to random error in suscepti- 
bility testing. Strain 78 was reported susceptible to pyra- 
zinamide but had a mutation in the pncA gene. It is 
possible that this mutation (51 His to Arg) causes no dis- 
ruption in pyrazinamidase activity. This case may also be 
attributable to testing error, because pyrazinamide sus- 
ceptibility is particularly difficult to test accurately 
The data presented here characterize a diverse sam- 
ple of Indian AI. tuberculosis strains with a high rate of 
drug resistance. In resource-poor developing countries, 
MDR TB poses a grave threat to public health, especially 
with the concurrent spread of HIV infection. The long 
duration of treatment required to cure TB combined with 
the cost of drugs makes compliance with anti-tuberculosis 
chemotherapy difficult to achieve in India.6 Most people 
in India seek health care from private providers who 
often treat TI3 improperly. 6,29~30 Directly Observed Ther- 
apy (DOT) programs are being piloted in India at a cost 
of $100 million to cover 30% of the country.” The most 
conservative estimate states that successful implementa- 
tion of DOT will provide a 4% increase per year ($8.3 
billion in 1993-1994) in India’s Gross Domestic Product 
owing to recovered productivity.31 Proper implementa- 
tion of DOT will require the extent of drug resistance to 
be assessed. Christian Medical College Hospital has one 
of the most comprehensive clinical microbiology labo- 
ratories in India, and even there, culturing and drug sus- 
ceptibility testing are not performed on all cases of TB, 
owing to the prohibitive cost. Sufficient funds should be 
allotted to TB control programs to permit routine cul- 
turing and drug susceptibility testing. 
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